Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell
Suitors Attracted To Advanced Medicines Manufacturers
Executive Summary
Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.
You may also be interested in...
Dynacure’s Antisense Approach To Rare Myopathies Gets Funding Boost
France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.
Austria’s Apeiron To Attack COVID-19 At Its Entry Point
Apeiron Biologics has fashioned a recombinant version of the enzyme to which SARS-CoV-2 is thought to bind, and with governmental help has started a Phase II study in Austria, Germany and Denmark.
Exscientia Links With Scripp Research’s Calibr To Apply AI To COVID-19
A transatlantic initiative is screening a US library of 15,000 pharmacologically active compounds for anti-COVID-19 activity, using artificial intelligence technologies.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports